Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 3Nasopharyngeal Carcinoma 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Thymoma 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Piebaldism 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced or Metastatic Solid Tumors 1

Interventions

Injections 6Fluorodeoxyglucose F18 4Cyclophosphamide 4Bevacizumab 4toripalimab 3fludarabine 2Specimen Handling 2Nivolumab 2zimberelimab 1tumor-cells apoptosis factor, human 1trametinib 1tislelizumab 1temsirolimus 1spartalizumab 1pembrolizumab 1pazopanib 1palbociclib 1olaparib 1lenvatinib 1etoposide phosphate 1enzalutamide 1envafolimab 1donafenib 1disitamab vedotin 1dabrafenib 1cemiplimab 1avelumab 1atezolizumab 1anlotinib 1WW Domain-Containing Oxidoreductase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Solid Tumor × envafolimab × Clear all
NCT04891198 2026-03-25

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

3D Medicines

Phase 2 Recruiting
126 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡